# Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

> **NCT03569475** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 501 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Levomilnacipran ER
- **DRUG:** Fluoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03569475
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-06
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569475, "Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03569475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*